Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) PT at $14.38

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have received a consensus rating of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.00.

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, April 10th. Royal Bank Of Canada reduced their target price on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 18th. Jefferies Financial Group restated a “buy” rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Finally, Needham & Company LLC reduced their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,967 shares of Bicycle Therapeutics stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total transaction of $29,297.97. Following the completion of the transaction, the chief executive officer owned 613,029 shares in the company, valued at approximately $3,009,972.39. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 9,992 shares of company stock worth $49,363. Company insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors have recently modified their holdings of the stock. Assetmark Inc. raised its stake in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares during the last quarter. Clearstead Advisors LLC raised its stake in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC purchased a new position in shares of Bicycle Therapeutics during the 4th quarter valued at about $71,000. Ausdal Financial Partners Inc. purchased a new position in shares of Bicycle Therapeutics during the 2nd quarter valued at about $70,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at about $71,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $5.15 on Thursday. The stock has a market capitalization of $359.01 million, a price-to-earnings ratio of -1.63 and a beta of 1.56. Bicycle Therapeutics has a 1-year low of $4.24 and a 1-year high of $9.36. The business has a fifty day moving average price of $5.00 and a 200-day moving average price of $6.15.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. On average, equities research analysts anticipate that Bicycle Therapeutics will post -1.99 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.